Teva Pharmaceutical Industries' (TEVA +0.3%) investigational anti-IL-5 inhibitor, reslizumab, achieves its primary endpoint of a reduction in the frequency of clinical asthma exacerbations (CAE) compared to placebo in two Phase 3 trials. Treatment with reslizumab reduced the frequency of CAE 50% and 60% in the studies (p value < 0.0001 for both). The results were highly statistically significant.
Reslizumab is an investigational humanized monoclonal antibody against interleukin-5 (IL-5). IL-5 has been shown to play an important role in the maturation, growth and chemotaxis of inflammatory white blood cells called eosinophils that are implicated in a number of allergic diseases.
The company expects to submit its regulatory applications in 1H 2015.